ERAS
Price
$2.38
Change
+$0.17 (+7.69%)
Updated
Oct 24, 04:59 PM (EDT)
Capitalization
675.13M
11 days until earnings call
Intraday Buy/Sell Signals
NVAX
Price
$8.52
Change
+$0.16 (+1.91%)
Updated
Oct 24, 04:59 PM (EDT)
Capitalization
1.38B
11 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ERAS vs NVAX

Header iconERAS vs NVAX Comparison
Open Charts ERAS vs NVAXBanner chart's image
Erasca
Price$2.38
Change+$0.17 (+7.69%)
Volume$15.22K
Capitalization675.13M
Novavax
Price$8.52
Change+$0.16 (+1.91%)
Volume$56.01K
Capitalization1.38B
ERAS vs NVAX Comparison Chart in %
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. NVAX commentary
Oct 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a StrongBuy and NVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 25, 2025
Stock price -- (ERAS: $2.38 vs. NVAX: $8.52)
Brand notoriety: ERAS: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 71% vs. NVAX: 51%
Market capitalization -- ERAS: $675.13M vs. NVAX: $1.38B
ERAS [@Biotechnology] is valued at $675.13M. NVAX’s [@Biotechnology] market capitalization is $1.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $108.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileNVAX’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • NVAX’s FA Score: 1 green, 4 red.
According to our system of comparison, NVAX is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while NVAX’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 4 bearish.
  • NVAX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ERAS and NVAX are a good buy in the short-term.

Price Growth

ERAS (@Biotechnology) experienced а -1.65% price change this week, while NVAX (@Biotechnology) price change was +5.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.97%. For the same industry, the average monthly price growth was +11.13%, and the average quarterly price growth was +63.98%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

NVAX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVAX($1.38B) has a higher market cap than ERAS($675M). NVAX YTD gains are higher at: 5.970 vs. ERAS (-5.179). NVAX has higher annual earnings (EBITDA): 496M vs. ERAS (-135.93M). NVAX has more cash in the bank: 612M vs. ERAS (301M). ERAS has less debt than NVAX: ERAS (49.4M) vs NVAX (228M). NVAX has higher revenues than ERAS: NVAX (1.08B) vs ERAS (0).
ERASNVAXERAS / NVAX
Capitalization675M1.38B49%
EBITDA-135.93M496M-27%
Gain YTD-5.1795.970-87%
P/E RatioN/A3.77-
Revenue01.08B-
Total Cash301M612M49%
Total Debt49.4M228M22%
FUNDAMENTALS RATINGS
NVAX: Fundamental Ratings
NVAX
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
52
P/E GROWTH RATING
1..100
11
SEASONALITY SCORE
1..100
49

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASNVAX
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCUPX20.820.08
+0.39%
NYLI PineStone U.S. Equity Class P
RLCAX9.33N/A
N/A
Columbia Disciplined Value A
PMDAX19.48N/A
N/A
Principal Small-MidCap Dividend Inc A
JLCWX78.58N/A
N/A
JHancock Fundamental Large Cap Core R6
AFOCX23.96N/A
N/A
Archer Focus